Holen Sie sich die Stockscreener-App
3.89
6.87%
0.25
Schlusskurs vom Vortag:
$3.64
Offen:
$3.65
24-Stunden-Volumen:
602.37K
Relative Volume:
0.70
Marktkapitalisierung:
$340.13M
Einnahmen:
$32.77M
Nettoeinkommen (Verlust:
$-101.98M
KGV:
-0.4048
EPS:
-9.6101
Netto-Cashflow:
$-112.43M
1W Leistung:
+19.69%
1M Leistung:
+7.16%
6M Leistung:
+9.27%
1J Leistung:
-80.74%
1-Tages-Spanne:
$3.54
$3.93
1-Wochen-Bereich:
$3.25
$4.07
52-Wochen-Spanne:
$1.35
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Firmenname
X 4 Pharmaceuticals Inc
Sektor
Branche
Telefon
857-529-8300
Adresse
61 NORTH BEACON STREET, BOSTON, MA
Vergleichen Sie XFOR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.89 | 318.27M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-05 | Fortgesetzt | Stifel | Buy |
| 2023-12-12 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-12-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | ROTH Capital | Buy |
| 2019-12-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-12-05 | Eingeleitet | B. Riley FBR | Buy |
| 2019-06-07 | Eingeleitet | Stifel | Buy |
| 2019-06-05 | Eingeleitet | Cowen | Outperform |
Alle ansehen
X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten
Does X4 Pharmaceuticals Inc (XFOR) offer a good opportunity for investors? - Setenews
X4 Pharmaceuticals, Inc. $XFOR Shares Sold by Pale Fire Capital SE - MarketBeat
Blood pressure drug recalled for possible cross-contamination - USA Today
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
XFOR Stock Update: Stifel Raises Target Price to $10.00 | XFOR S - GuruFocus
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness - BioSpace
Stronger 2025 Outlook And Fragile X Trial Start Might Change The Case For Investing In Mirum (MIRM) - Yahoo Finance
How X4 Pharmaceuticals Inc. stock reacts to oil prices2025 Technical Overview & Stepwise Swing Trade Plans - Newser
Is X4 Pharmaceuticals Inc. (48Q0) stock a safe buy pre earningsFed Meeting & Intraday High Probability Alerts - Newser
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Take off with X4 Pharmaceuticals Inc (XFOR): Get ready for trading - Setenews
Why pension funds invest in X4 Pharmaceuticals Inc. (48Q0) stockWeekly Earnings Recap & Weekly Breakout Opportunity Watchlist - Newser
Is X4 Pharmaceuticals Inc. stock positioned for long term growthJuly 2025 Gainers & Comprehensive Market Scan Reports - Newser
Will X4 Pharmaceuticals Inc. (48Q0) stock profit from AI boomTrade Ideas & Fast Exit and Entry Strategy Plans - Newser
An analyst sees good growth prospects for Nano X Imaging Ltd (NNOX) - Setenews
X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia (NASDAQ:XFOR) - Seeking Alpha
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome - Yahoo Finance
X4 Pharmaceuticals (NASDAQ:XFOR) Stock Rating Lowered by Wall Street Zen - Defense World
Layoff Tracker: Valneva Terminates 30 Amid Site Closure - BioSpace
SKYRIZI® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance - Investing News Network
Will X4 Pharmaceuticals Inc. stock deliver long term returns2025 Momentum Check & Free High Accuracy Swing Entry Alerts - BỘ NỘI VỤ
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness - Morningstar
Can X4 Pharmaceuticals Inc. stock deliver sustainable ROE2025 Macro Impact & Low Volatility Stock Recommendations - moha.gov.vn
Earnings Report: Can X4 Pharmaceuticals Inc. stock sustain institutional interestTrade Risk Summary & AI Powered Buy and Sell Recommendations - BỘ NỘI VỤ
Investors Don't See Light At End Of Universe Pharmaceuticals INC's (NASDAQ:UPC) Tunnel And Push Stock Down 31% - simplywall.st
Looking at the Narrative for X4 Pharmaceuticals After Leadership Changes and New Financing - Yahoo Finance
Head-To-Head Contrast: Werewolf Therapeutics (NASDAQ:HOWL) versus X4 Pharmaceuticals (NASDAQ:XFOR) - Defense World
X4 Pharmaceuticals (NASDAQ:XFOR) Upgraded to Hold at Wall Street Zen - Defense World
Is X4 Pharmaceuticals Inc. stock positioned for digital transformation2025 Price Action Summary & Comprehensive Market Scan Insights - newser.com
Why X4 Pharmaceuticals Inc. (48Q0) stock remains top ratedWeekly Trend Report & AI Enhanced Trading Alerts - newser.com
Will X4 Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Short Interest & Growth Oriented Trading Recommendations - newser.com
X4 Pharmaceuticals Inc (XFOR) Performance and Fundamentals Dashboard tells a completely different story - Setenews
How to build a dashboard for X4 Pharmaceuticals Inc. stockWeekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
WHIM Syndrome Research Analysis Report 2025-2035: Market Advances as X4 Pharmaceuticals Leads Innovation in CXCR4-Targeted Therapies - Yahoo Finance
Prescription Drug Costs - Britannica
What moving averages say about X4 Pharmaceuticals Inc.2025 Year in Review & Momentum Based Trading Ideas - newser.com
Why X4 Pharmaceuticals Inc. stock could benefit from AI revolutionPortfolio Return Summary & Fast Gaining Stock Strategy Reports - newser.com
Finanzdaten der X 4 Pharmaceuticals Inc-Aktie (XFOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):